Evaluation of the Effect of Clobetasol Propionate on Circulating Cortisol and Growth Velocity in Children with Atopic Dermatitis: A Modelling and Simulation Study

Surface area affected by AD should be considered when assessing the risk of systemic side effects. CP can be applied up to 20% of the body surface area of a child (>1-year-old) without clinically relevant changes to circulating cortisol levels. In contrast to the systemic effects of oral corticosteroids, the short-term use of CP has no impact the GV of paediatric subjects with AD.